Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Adjuvant Chemo After Surgery for Urothelial Carcinoma
J Clin Oncol; ePub 2017 Jan 3; Seisen, et al
People who received adjuvant chemotherapy after radical nephroureterectomy for upper tract urothelial carcinoma tended to survive longer than those who underwent observation only in a study involving more than 3,200 individuals.
Investigators looked at survival in patients who underwent treatment vs observation only. They also evaluated treatment effect according to age, gender, comorbidities, pathologic stage, and surgical margin status. Among the results:
- ~Three fourths of patients with pT3/T4 and/or pN+ disease had chemo; the remainder underwent observation only.
- Median overall survival was ~47 months in patients receiving chemotherapy, vs ~36 months in those undergoing observation only.
- The benefit was seen in all subgroups.
Seisen T, Krasnow R, Bellmunt J, et al. Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma. [Published online ahead of print January 3, 2017]. J Clin Oncol. doi:10.1200/JCO.2016.69.4141.